SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Jacqueline du Pré — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJacqueline Mary du Pré
Date of birth1945-01-26
IdentifiersMRN HR-ML039-SYN-TD; SSN (made up) 000-39-7062
Document date1973-04-27
AuthorImogen Thackeray-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Second half-dose of the first ocrelizumab course. [S]

History of Present Illness

Ms. du Pré comes on the day of her second 300 mg dose of ocrelizumab. The three days of intravenous methylprednisolone a month ago caused a few nights of poor sleep and a metallic taste, and within two weeks the feeling in her fingers began to come back. The first infusion two weeks ago caused an itchy throat and flushing an hour in, which settled when the rate was slowed. She has worked with the occupational therapist on finger exercises and practices in 20-minute blocks, about two hours a day, and has played through slow movements without losing her place. The electric feeling on bending her head is fainter. Her blood tests before the first infusion were normal. She is less tired. [S]

ElementDetail
TreatmentMethylprednisolone 1 g for 3 days; ocrelizumab 300 mg two weeks ago; second 300 mg today
Infusion reactionMild throat itch and flushing with the first dose, settled by slowing the rate
Hand functionFeeling returning; practicing two hours a day in short blocks
VaccinationHepatitis B dose 2 today

Review of Systems

SystemResultFinding
ConstitutionalNegativeLess tired; no fever
NeurologicalPositiveTingling in the left fingertips, less than before; Lhermitte's sign fainter; no new symptoms
Ears, nose, mouth, and throatNegativeThroat itch with the first infusion only
GenitourinaryNegativeNo urinary symptoms
IntegumentaryNegativeNo rash
PsychiatricNegativeHopeful; PHQ-9 5; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days1 g daily for 3 daysIntravenous route1973-03-24 to 1973-03-26completedS
Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth dailyOne capsule dailyOral route1973-03-23activeS
Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion300 mg on days 1 and 15, then 600 mg every 6 monthsIntravenous route1973-04-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1973-04-27Body height173cmS
1973-04-27Body weight64.6kgS
1973-04-27Body mass index (BMI) [Ratio]21.6kg/m2S
1973-04-27Systolic blood pressure118mm[Hg]S
1973-04-27Diastolic blood pressure74mm[Hg]S
1973-04-27Heart rate72/minS
1973-04-27Respiratory rate14/minS
1973-04-27Body temperature36.6CelS
1973-04-27Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1973-04-27Hemoglobin [Mass/volume] in Blood13.6g/dL12-15.5 g/dLNormalS
1973-04-27Leukocytes [#/volume] in Blood by Automated count7.910*3/uL4-11 10*3/uLNormalS
1973-04-27Lymphocytes [#/volume] in Blood by Automated count1.610*3/uL1-4.8 10*3/uLNormalS
1973-04-27Platelets [#/volume] in Blood by Automated count25210*3/uL150-400 10*3/uLNormalS
1973-04-27Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
1973-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-35 U/LNormalS
1973-04-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-35 U/LNormalS
1973-04-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1973-04-279-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]20.5sS
1973-04-279-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]23sS

Physical Exam

Vital signs recorded on 1973-04-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 64.6 kg, up 1.2 kg after steroids; blood pressure 118/74
NeurologicalVibration and joint position sense now only slightly reduced in the left fingers; no wandering of the fingers; strength normal; Lhermitte's sign faint. Nine-hole peg test 20.5 seconds right, 23.0 seconds left
SkinNo rash
PsychiatricBrighter and engaged

Problems

ProblemClinical statusVerificationCodeProvenance
Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this weekresolvedconfirmed R20.2S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit.
Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosisactiveconfirmed G35.AS — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973.
Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosisactiveconfirmed E55.9S — Synthetic finding.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with lymphocytesBefore each ocrelizumab doseCompleted todayHemoglobin 13.6 g/dL, white cells 7.9, lymphocytes 1.6, platelets 252
LaboratoryLiver tests and glucoseAfter high-dose steroids and before each doseCompleted todayALT 21 U/L, AST 22 U/L; glucose 90 mg/dL
LaboratoryPregnancy testBefore each ocrelizumab doseCompleted todayUrine pregnancy test negative
LaboratoryHepatitis B, HIV and other screening before B-cell therapyBefore the first doseUp to dateReviewed at the diagnosis visit: no hepatitis B infection and not immune, so vaccination continues
Medication safetyInfusion reactionsWith each infusionCompleted todayMild reaction with dose 1 (throat itch, flushing); premedication and a slower rate today
Medication safetyVaccinationComplete series where possibleCompleted todayHepatitis B dose 2 today; recombinant zoster dose 2 due in two to six months after dose 1
ExaminationHand function: nine-hole peg test, both handsAt diagnosis, after a relapse, and at each reviewCompleted today20.5 seconds right, 23.0 seconds left
ReferralOccupational therapyThrough recovery from the relapseUp to dateProgram started a week after the diagnosis visit
ImagingRe-baseline MRI of the brainThree to six months after starting a disease-modifying therapyDueBooked for about three months after the first dose
Laboratory25-hydroxyvitamin DAbout three months after starting replacementDueWith the re-baseline MRI visit
SurveyMood and anxiety (PHQ-9, GAD-7)At diagnosis and at each reviewCompleted todayPHQ-9 5; item 9 scored 0
Self-managementFatigue: causes and managementEach reviewCompleted todayLess tired; pacing practice in short blocks with rests

Goal progress:

Immunizations given today: Hepatitis B vaccine (adjuvanted, two-dose series), dose 2 [S]

Guideline basis: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021); Hauser SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376(3):221-234 (PMID 28002679) (2017); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019)

Follow-up: Re-baseline MRI and review in about ten weeks; occupational therapy continues; call for fever, urinary symptoms or any new neurological symptom. Next scheduled visit 1973-07-13: three months on ocrelizumab: re-baseline MRI, B-cell depletion, fatigue, vitamin D and hand function. [S]